drugset / Trial / NCT04245748

Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

NCT04245748

Phase 4 Recruiting 84 enrolled University of Cincinnati
RandomizedParallel-groupDouble-blindTreatment

Summary

Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.

Timeline

Start
2020-03-01
Primary completion
2025-07-30
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule
Comparator Escitalopram Small molecule